Treatment
Sox clinical trials
We’re tracking 34 recruiting studies that include Sox, each written for real people, not researchers, below.
Recruiting studies
- NCT06829797RecruitingPhase 2
Iparomlimab and chemotherapy vs chemotherapy alone for stomach cancer
This trial tests whether adding an immunotherapy drug (Iparomlimab and Tuvonralimab, combined as QL1706) to standard chemotherapy before surgery works better than chemotherapy alone for people with locally advanced stomach or gastroesophageal junction cancer that can be surgically removed.
Jinan, ShandongAges 18–75 - NCT07474324RecruitingPhase 2
Targeted therapy plus chemo vs chemo alone for stage 3 stomach cancer
This trial tests adding disitamab vedotin (a drug that targets HER2) to standard chemotherapy (SOX) after surgery for stage 3 stomach cancer. The goal is to see if the combination works better than chemo alone to prevent cancer from coming back.
Nanjing, JiangsuAges 18–75 - NCT06925243RecruitingPhase 3
Apatinib, Sintilimab, and Chemo for Intestinal Gastric Cancer
This phase 3 trial tests adding the targeted drug apatinib to a standard combination of sintilimab (immunotherapy) and chemotherapy (SOX regimen) given before surgery for a specific type of stomach or gastroesophageal junction cancer (intestinal type, HER2-negative). The goal is to see if the three-drug combination works better than the two-drug combination in shrinking the tumor and improving outcomes before surgery.
Lanzhou, GansuAges 18–75 - NCT07263386RecruitingPhase 2
Immunotherapy plus chemo for PD-L1-positive stomach cancer
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy (SOX) after surgery helps prevent stomach cancer from returning. It’s for people whose tumors have a protein called PD-L1 and who had cancer in at least 7 lymph nodes.
Nanjing, JiangsuAges 18–75 - NCT05593458RecruitingPhase 3
Stomach cancer surgery before chemo: artery-based or drip chemo
This trial compares two ways of giving chemotherapy before surgery for locally advanced stomach or stomach–esophagus cancer: chemo sent through an artery versus chemo given through an IV line. It also studies adding PD-1 immunotherapy to see which approach works better and is safer.
Hangzhou, ZhejiangAges 18–75 - NCT07867392RecruitingPhase 2
New drug combo before surgery for stomach cancer
This study tests a combination of two immunotherapy drugs plus chemotherapy before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06277024Recruiting
Combination therapy for advanced HER2-negative stomach cancer
This trial tests a combination of immunotherapy (candenizumab), a targeted therapy (lenvatinib), and chemotherapy (SOX regimen) for advanced HER2-negative stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if this combination is safe and works better than standard treatments.
Fuzhou, FujianAges 18–75 - NCT07353684RecruitingPhase 2
Adebrelimab plus apatinib with chemo for gastric cancer
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
Beijing, Beijing MunicipalityAges 18–75 - NCT07356466Enrolling by invitationEarly Phase 1
Combination therapy vs. standard chemo for advanced stomach cancer
This trial tests whether adding two newer drugs (pucotenlimab and lenvatinib) to standard chemotherapy (SOX) works better than chemotherapy alone for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if the combination slows cancer growth.
Fuzhou, FujianAges 18–75 - NCT07026149RecruitingPhase 2
Combination therapy before surgery for stomach cancer
This trial tests a combination of radiation, chemotherapy (SOX), and two targeted drugs (apatinib and camrelizumab) before and after surgery for stomach or gastroesophageal junction cancer. It aims to see if this approach is safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07023315RecruitingPhase 3
Study of cadonilimab plus SOX before and after surgery for stomach cancer
This trial tests if adding the drug cadonilimab to standard chemotherapy (SOX) before and after surgery can help treat stomach or gastroesophageal junction cancer that can be removed. The goal is to see if this combination improves outcomes for patients.
Beijing, Beijing MunicipalityAges 18–75 - NCT06949033RecruitingPhase 3
Cadonilimab with chemo for stomach cancer
This trial tests a new combination of immunotherapy (cadonilimab) and chemotherapy before and after surgery for a specific type of advanced stomach or gastroesophageal junction cancer. It aims to see if adding this immunotherapy helps shrink tumors and improve outcomes.
Lanzhou, GansuAges 18–75 - NCT06766305RecruitingPhase 1/Phase 2
QL1706 combined with SOX before and after stomach cancer surgery
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
Hangzhou, ZhejiangAges 18–75 - NCT06826079RecruitingPhase 2
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT06766578RecruitingPhase 2
Low-dose radiation plus immunotherapy and chemo before gastric cancer surgery
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
Jinan, ShandongAges 18–75 - NCT06510010RecruitingPhase 2
Chemo plus H. pylori treatment for advanced stomach cancer
This trial tests whether adding H. pylori bacteria treatment to standard chemotherapy (before and after surgery) can improve outcomes for people with locally advanced stomach cancer. It combines oxaliplatin and S-1 chemo with antibiotics to clear the infection.
GuangzhouAges 18–75 - NCT04483076RecruitingPhase 3
Chemo before stomach surgery with different cycles
This trial studies whether giving oxaliplatin plus S-1 (SOX) chemotherapy before stomach surgery works best when given for different cycle lengths. It may help shrink stage III gastric cancer before a standard D2 gastrectomy and improve outcomes.
Beijing, Beijing MunicipalityAges 18–70 - NCT04908566RecruitingPhase 2
PD-1 immunotherapy plus chemotherapy before and after gastric surgery
This trial studies whether adding a PD-1 immune therapy to chemotherapy around the time of surgery can improve outcomes for people with locally advanced stomach or stomach–esophagus junction cancer. It aims to better control the cancer before and reduce the chance it comes back after surgery.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT04989985RecruitingPhase 2
SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Guangzhou, GuangdongAges 18–75 - NCT06371586RecruitingPhase 2
Neo-Sequence 2: New drug combo for advanced stomach cancer
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
BeijingAges 18–75 - NCT06196697RecruitingPhase 2
New immunotherapy combo for advanced stomach cancer
This clinical trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus chemotherapy as the first treatment for advanced stomach or gastroesophageal junction cancer. It aims to see if this combination helps control the cancer better than standard therapy.
HarbinAges 18–75 - NCT07788196RecruitingPhase 2
Adding anti-HER2 therapy after surgery for early-stage gastric cancer
This trial tests whether adding a targeted therapy (anti-HER2) to standard chemotherapy after surgery can improve outcomes for people with early-stage gastric cancer that has high HER2 levels. It aims to see if the combination is more effective than chemotherapy alone.
Xi'an, ShaanxiAges 18 years+ - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT07569068RecruitingPhase 2
Combination Cancer Drugs Before Surgery for Stomach Cancer
This trial tests whether giving immunotherapy and chemotherapy drugs before surgery can help treat stomach cancer that has a specific protein marker (claudin 18.2). The goal is to shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Shanghai, Huangpu DistrictAges 18 years+
What Sox is being studied for
Conditions with recruiting Sox studies.
Common questions
- Are there clinical trials studying Sox?
- Yes. Clin2 currently lists 34 recruiting studies that include Sox, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Sox trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Sox an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Sox or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.